470473-71-3

Upstream product

• 470473-70-2 [allyloxycarbonyl-(2-{2-[(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-acetylamino}-ethyl)-amino]-acetic acid 
• 470473-86-0 [allyloxycarbonyl-(2-{2-[(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-acetylamino}-ethyl)-amino]-acetic acid methyl ester 
• 470473-74-6 [(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-(2,2,2-trichloro-ethoxycarbonyl)-amino]-acetic acid 
• 221554-79-6 methyl N-<2-(N-Mmt)aminoethyl>-N-glycinate 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 172405-21-9 methyl N-<2-((4-methoxyphenyl)-diphenylmethyl)aminoethyl> glycinate 
• 470473-87-1 C₅₁H₆₂Cl₆N₈O₁₄ 

Relevant academic research and scientific papers

Cyclic PNA hexamer-based compound: Modelling, synthesis and inhibition of the HIV-1 RNA dimerization process

A cyclic molecule constituted by (i) a hexameric PNA moiety complementary to six among the nine residues of the dimerization initiation site loop of HIV-1 and (ii) a spacer tethering the N- to the C-extremities of the PNA, has been elaborated to inhibit the dimerization process of HIV-1 genome. This compound has been synthesized following a liquid-phase procedure (fully protected backbone approach). Preliminary agarose gel electrophoresis analyses have shown that the cyclic PNA conjugate is able to inhibit the HIV-1 dimerization.